Semnur Pharmaceuticals, Inc., a wholly owned subsidiary of Scilex Holding Company, announced the signing of a letter of intent for a proposed business combination with Denali Capital Acquisition Corp., a special purpose acquisition company. The deal includes a pre-transaction equity value of Semnur of up to $2 billion and expected gross proceeds of up to $40 million. The business combination aims to create a publicly traded biopharma company focused on the development of a non-opioid product, SP-102 (SEMDEXA), currently in Phase 3 trials for treating lumbosacral radicular pain or sciatica. If approved, the product could significantly advance the treatment of chronic pain conditions. Scilex is expected to remain the majority holder post-transaction. The completion of this business combination is subject to several conditions, including negotiation of a definitive merger agreement, board and shareholder approvals, and necessary regulatory filings. This transaction highlights the potential of SP-102, which has already demonstrated positive Phase 3 trial results and achieved FDA Fast Track status, further underscoring its market potential.

Healthcare – Pharmaceutical, Finance – Private Equity/Venture Capital,United States

https://mergersacquisitions.einnews.com/pr_news/724707020/semnur-pharmaceuticals-inc-a-wholly-owned-subsidiary-of-scilex-holding-company-and-denali-capital-acquisition-corp-nasdaq-deca-enter-into-a?ref=rss&ecode=Q1vNcweEggLWKz7L&utm_source=RSSNews&utm_medium=rss&utm_campaign=Mergers+%26+Acquisitions+News&utm_content=article